Home » Critical Path Teams With EU’s IMI to Speed Medicine Progress
Critical Path Teams With EU’s IMI to Speed Medicine Progress
A new memorandum of understanding (MoU) between the U.S. Critical Path Institute (C-Path) and the EU’s Innovative Medicines Initiative (IMI) may help accelerate drug development by driving agreements on testing methods. The two parties said June 14 that they had signed the MoU to further the missions of both organizations.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May